Mondal, J., Zhang, J., Qing, F., Li, S., Kumar, D., Huse, J. T., & Giancotti, F. G. (2025). Brd7 loss reawakens dormant metastasis initiating cells in lung by forging an immunosuppressive niche. Nature Communications, 16(1). https://doi.org/10.1038/s41467-025-56347-2

Gonzalez-Lopez, E., Maurer, M. S., & Garcia-Pavia, P. (2025). Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine. European Heart Journal. https://doi.org/10.1093/eurheartj/ehae811

Wang, B. Z., Morsink, M. A. J., Kim, S. W., Luo, L. J., Zhang, X., Soni, R. K., Lock, R. I., Rao, J., Kim, Y., Zhang, A., Neyazi, M., Gorham, J. M., Kim, Y., Brown, K., DeLaughter, D. M., Zhang, Q., McDonough, B., Watkins, J. M., Cunningham, K. M., … Vunjak-Novakovic, G. (2025). Cardiac fibroblast BAG3 regulates TGFBR2 signaling and fibrosis in dilated cardiomyopathy. Journal of Clinical Investigation, 135(1). https://doi.org/10.1172/jci181630

Sharma, M. R., Johnson, M. L., Puzanov, I., Sznol, M., Mckean, M., Gainor, J. F., Spira, A., Henick, B., Tolcher, A. W., Chen, C. T., El-Khoueiry, A., Broderick, J., Peng, L., Che, J., Cao, L., Wilson, D., Lathers, D., Horak, C., Feltquate, D., & Luke, J. J. (2024). 758 GLIMMER-01: phase 1/2 trial of a first-in-class bi-sialidase (E-602) in combination with cemiplimab in patients with PD-(L)1-resistant solid tumors. Regular and Young Investigator Award Abstracts, A862–A862. https://doi.org/10.1136/jitc-2024-sitc2024.0758

Markosyan, N., Kim, I.-K., Arora, C., Quinones-Ware, L., Joshi, N., Cheng, N., Schechter, E. Y., Tobias, J. W., Hochberg, J. E., Corse, E., Liu, K., Rodriguez DiBlasi, V., Chan, L.-C. (Eric), Smyth, E. M., FitzGerald, G. A., Stanger, B. Z., & Vonderheide, R. H. (2024). Pivotal roles for cancer cell–intrinsic mPGES-1 and autocrine EP4 signaling in suppressing antitumor immunity. JCI Insight, 9(21). https://doi.org/10.1172/jci.insight.178644

Rathkopf, D. E., Patel, M. R., Choudhury, A. D., Rasco, D., Lakhani, N., Hawley, J. E., Srinivas, S., Aparicio, A., Narayan, V., Runcie, K. D., Emamekhoo, H., Reichert, Z. R., Nguyen, M. H., Wells, A. L., Kandimalla, R., Liu, C., Suryawanshi, S., Han, J., Wu, J., … Armstrong, A. J. (2024). Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Annals of Oncology. https://doi.org/10.1016/j.annonc.2024.09.005

Small-Saunders, J. L., Sinha, A., Bloxham, T. S., Hagenah, L. M., Sun, G., Preiser, P. R., Dedon, P. C., & Fidock, D. A. (2024). tRNA modification reprogramming contributes to artemisinin resistance in Plasmodium falciparum. Nature Microbiology, 9(6), 1483–1498. https://doi.org/10.1038/s41564-024-01664-3

Garcia‐Pavia, P., Grogan, M., Kale, P., Berk, J. L., Maurer, M. S., Conceição, I., Di Carli, M., Solomon, S. D., Chen, C., Yureneva, E., Vest, J., & Gillmore, J. D. (2024). Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin‐mediated amyloidosis with polyneuropathy. European Journal of Heart Failure, 26(2), 397–410. Portico. https://doi.org/10.1002/ejhf.3138

Fu, J., Li, S., Ma, H., Yang, J., Pagnotti, G. M., Brown, L. M., Weiss, S. J., Mapara, M. Y., & Lentzsch, S. (2023). The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-39769-8

Hoffman, J. E., Bumma, N., Richter, J., Dhodapkar, M. V., Lee, H. C., Suvannasankha, A., Houde, C. A., Maly, J. J., Shah, M. R., Baz, R., Namburi, S., Wu, K. L., Pianko, M., Ye, J. C., Lentzsch, S., Silbermann, R., Min, C.-K., Vekemans, M.-C., Munder, M., … Jagannath, S. (2023). Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment. Blood, 142(Supplement 1), 3359–3359. https://doi.org/10.1182/blood-2023-179170

Qian, J., Ryeom, S., Daugherty, B. L., Lederman, S., & Wang, T. C. (2023). 481 A CXCR4 partial agonist TFF2-MSA sensitized advanced gastric cancer to PD-1 blockade by systematically reducing PMN-MDSC accumulation, immunosuppression, and generation in bone marrow. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0481

Ruan, J., Zain, J., Palmer, B., Jovanovic, B., Mi, X., Swaroop, A., Winter, J. N., Gordon, L. I., Karmali, R., Moreira, J., Petrich, A. M., & Pro, B. (2023). Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma. Blood Advances, 7(19), 5771–5779. https://doi.org/10.1182/bloodadvances.2023009767

Ko, A. H., Kim, K.-P., Siveke, J. T., Lopez, C. D., Lacy, J., O’Reilly, E. M., Macarulla, T., Manji, G. A., Lee, J., Ajani, J., Alsina Maqueda, M., Rha, S.-Y., Lau, J., Al-Sakaff, N., Allen, S., Lu, D., Shemesh, C. S., Gan, X., Cha, E., & Oh, D.-Y. (2023). Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. The Oncologist, 28(6), 553-e472. https://doi.org/10.1093/oncolo/oyad022

Park, K., Sabari, J. K., Haura, E. B., Shu, C. A., Spira, A., Salgia, R., Reckamp, K. L., Sanborn, R. E., Govindan, R., Bauml, J. M., Curtin, J. C., Xie, J., Roshak, A., Lorenzini, P., Millington, D., Thayu, M., Knoblauch, R. E., & Cho, B. C. (2023). Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer, 178, 166–171. https://doi.org/10.1016/j.lungcan.2023.02.008

Bumma, N., Richter, J., Brayer, J., Zonder, J. A., Dhodapkar, M., Shah, M. R., Hoffman, J. E., Mawad, R., Maly, J. J., Lentzsch, S., Suvannasankha, A., Roy, P., Dey, J., Chokshi, D., Boyapati, A., Visich, J., Houvras, Y., Rodriguez Lorenc, K., Kroog, G. S., & Jagannath, S. (2022). Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study. Blood, 140(Supplement 1), 10140–10141. https://doi.org/10.1182/blood-2022-159969

Mohyuddin, G. R., Chakraborty, R., Calip, G., Ascha, M. S., Wang, X., Rubinstein, S., Tuchman, S. A., Costa, L. J., Haaland, B., Giri, S., Mian, H. S., Fonseca, R., & Sborov, D. W. (2022). Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy. Blood, 140(Supplement 1), 5223–5224. https://doi.org/10.1182/blood-2022-165541

Maynard, R., Fitzgerald, A., Nasir, A., Glasgow, E., Jablonski, S., Veken, P. V. D., Pearson, G., Mace, E., & Weiner, L. (2022). 1012 Fibroblast activation protein regulates human natural killer cell migration. Regular and Young Investigator Award Abstracts, A1055–A1055. https://doi.org/10.1136/jitc-2022-sitc2022.1012

Capaccione, K. M., Doubrovin, M., Braumuller, B., Leibowitz, D., Bhatt, N., Momen-Heravi, F., Molotkov, A., Kissner, M., Goldner, K., Soffing, M., Ali, A., & Mintz, A. (2022). Evaluating the Combined Anticancer Response of Checkpoint Inhibitor Immunotherapy and FAP-Targeted Molecular Radiotherapy in Murine Models of Melanoma and Lung Cancer. Cancers, 14(19), 4575. https://doi.org/10.3390/cancers14194575

Ryu, Y. K., Ricker, E. C., Soderquist, C. R., Francescone, M. A., Lipsky, A. H., & Amengual, J. E. (2022). Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma. Journal of Clinical Medicine, 11(16), 4928. https://doi.org/10.3390/jcm11164928

van der Sluijs, P. J., Joosten, M., Alby, C., Attié-Bitach, T., Gilmore, K., Dubourg, C., Fradin, M., Wang, T., Kurtz-Nelson, E. C., Ahlers, K. P., Arts, P., Barnett, C. P., Ashfaq, M., Baban, A., van den Born, M., Borrie, S., Busa, T., Byrne, A., Carriero, M., … Santen, G. W. E. (2022). Discovering a new part of the phenotypic spectrum of Coffin-Siris syndrome in a fetal cohort. Genetics in Medicine, 24(8), 1753–1760. https://doi.org/10.1016/j.gim.2022.04.010

Uriel, M., Oren, D., Yopes, M., Clerkin, K., Raikhelkar, J., Fried, J., Griffin, J., Gaine, M., Restaino, S., Lee, S., Choe, J., Jennings, D., Topkara, V., Takeda, K., Naka, Y., Majure, D., Yuzefpolskaya, M., Colombo, P., Latif, F., … Habal, M. (2022). The Efficacy and Safety of Belatacept in Heart Transplant Recipients. The Journal of Heart and Lung Transplantation, 41(4), S338. https://doi.org/10.1016/j.healun.2022.01.1400